We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+47.61%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.49B
AUM Growth
+$63.7M
Cap. Flow
-$72.5M
Cap. Flow %
-4.85%
Top 10 Hldgs %
49.88%
Holding
81
New
8
Increased
11
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$22.9M
2
AXSM icon
Axsome Therapeutics
AXSM
+$19.4M
3
PRME icon
Prime Medicine
PRME
+$13.3M
4
PCVX icon
Vaxcyte
PCVX
+$12.8M
5
BCAB icon
BioAtla
BCAB
+$12.4M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$38.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$27.9M
3
ACLX
Arcellx
ACLX
+$22.3M
4
ACET icon
Adicet Bio
ACET
+$12.5M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$230M 15.38%
2,090,000
+110,842
+6% +$7.19M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$81.5M 5.46%
1,576,872
+98,872
+7% +$5.24M
ACLX
3
DELISTED
Arcellx
ACLX
$64.3M 4.3%
2,075,000
-974,173
-32% -$22.3M
MLTX icon
4
MoonLake Immunotherapeutics
MLTX
$1.56B
$63.7M 4.26%
6,065,001
– –
RNAM
5
DELISTED
Avidity Biosciences
RNAM
$61.3M 4.1%
2,762,115
+750,000
+37% +$11.2M
JBIO
6
Jade Biosciences
JBIO
$1.18B
$57.3M 3.84%
55,918
-10,673
-16% -$7.75M
DSGN icon
7
Design Therapeutics
DSGN
$751M
$52.8M 3.54%
5,150,000
+150,000
+3% +$2.03M
ERAS icon
8
Erasca
ERAS
$6.15B
$46.6M 3.12%
10,813,246
+307,692
+3% +$2.09M
RVMD icon
9
Revolution Medicines
RVMD
$38.5B
$45.1M 3.02%
1,895,066
-100,000
-5% -$2.13M
ALT icon
10
Altimmune
ALT
$568M
$42.8M 2.86%
2,600,000
-842,863
-24% -$9.47M
VTYX
11
DELISTED
Ventyx Biosciences
VTYX
$35.4M 2.37%
1,080,643
+299,997
+38% +$8.89M
ETNB
12
DELISTED
89bio
ETNB
$32.5M 2.17%
+2,550,000
New +$22.9M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.2B
$32.1M 2.15%
1,100,000
-210,000
-16% -$4.84M
BCAB icon
14
BioAtla
BCAB
$5.34M
$30.4M 2.03%
73,607
+29,985
+69% +$12.4M
TNGX icon
15
Tango Therapeutics
TNGX
$4.21B
$29.8M 2%
4,116,949
– –
BMEA icon
16
Biomea Fusion
BMEA
$88.2M
$26.7M 1.79%
3,170,872
– –
EWTX icon
17
Edgewise Therapeutics
EWTX
$4.28B
$26.3M 1.76%
2,946,887
-105,102
-3% -$985K
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.64B
$25.9M 1.73%
200,000
– –
TARS icon
19
Tarsus Pharmaceuticals
TARS
$2.55B
$25.5M 1.7%
1,736,422
-235,000
-12% -$3.89M
AXSM icon
20
Axsome Therapeutics
AXSM
$11.7B
$25.1M 1.68%
+325,000
New +$19.4M
ATXS
21
DELISTED
Astria Therapeutics
ATXS
$24.6M 1.64%
1,650,000
+450,000
+38% +$4.64M
RAIN
22
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$23.8M 1.59%
2,978,660
+652,000
+28% +$4.09M
GLUE icon
23
Monte Rosa Therapeutics
GLUE
$1.82B
$22M 1.47%
2,893,717
-100,000
-3% -$833K
VECT
24
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$22M 1.47%
2,536,617
– –
KRTX
25
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$21.6M 1.45%
110,000
-40,000
-27% -$8.58M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Cormorant Asset Management held 81 positions worth $1.49B, up 4.5% from $1.43B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cormorant Asset Management withdrew a net $72.5M in Q4 2022, closing 8 positions and reducing 24 holdings. Its most notable exit was Gossamer Bio, an estimated $38.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in 89bio worth $32.5M.

  • Cormorant Asset Management's largest Q4 2022 buy was 89bio: 2,550,000 shares worth $32.5M.
  • Cormorant Asset Management added most to BioAtla in Q4 2022, an estimated $12.4M increase.
  • Cormorant Asset Management's biggest Q4 2022 reduction was Arcellx, cutting an estimated $22.3M.
  • Cormorant Asset Management fully exited Gossamer Bio in Q4 2022, selling an estimated $38.3M.
  • Cormorant Asset Management's ten largest holdings make up 50% of its $1.49B portfolio in Q4 2022.
  • Cormorant Asset Management opened 8 new positions and closed 8 in Q4 2022.
  • Cormorant Asset Management's portfolio value rose 4.5% quarter-over-quarter to $1.49B.

Based on Cormorant Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.